Skip to content

Quince Therapeutics, Inc.

QNCX

CIK 0001662774

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$8.61M
−47.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.13
−28.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$29.47M
Q1 May 2026
Cash
$18.16M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
16.3M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings